An IP Australia delegate has rejected German drug maker Ever Neuro Pharma’s claim that extensive experimental evidence was needed to prove the usefulness of a Parkinson’s drug developed by UK-based Britannia Pharmaceuticals.
Subscribe for instant access to all Lawyerly content.
